Safety and Efficacy of Autologous Progenitor Cell Transplantation for Therapeutic Angiogenesis in Patients With Critical Limb Ischemia

Abstract

The TACT regimen improved CLI in patients with Buerger's disease but not in those with ASO-HD in this small study. In responders, post procedural circulating CD34+ and CD133+ cells persistently increased for 1 month (ClinicalTrials.gov Identifier: NCT00145262, TACT-NAGOYA).